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ABSTRACT 
Introduction. In the setting of atrial fibrillation (AF), left atrial appendage (LAA) closure using the Watch-
manTM device (WD) was proven to effectively prevent stroke, systemic embolism and cardiovascular death 
when compared with warfarin therapy. However, this procedure is potentially associated with the risk of 
complications, including device-attached thrombus formation.
Case presentation. We report a case of a 65-year-old woman with permanent non-valvular AF, a history 
of ischemic stroke on warfarin treatment, hypertension, diabetes mellitus, heart failure with preserved left 
ventricular ejection fraction, labile values of the international normalized ratio, enlarged left atrium (LA) and 
spontaneous echo contrast in echocardiography, who was qualified for percutaneous LAA closure using the 
WD. The pre-procedural patient assessment indicated high thromboembolic (CHA2DS2-Vasc Score = 5) 
and bleeding risk (HAS-BLED Score = 4), and optimal morphology of LAA in transesophageal echocardi-
ography (TEE). After a successful procedure using a 30 mm-sized WD, and despite appropriate antiplatelet 
and anticoagulation therapy, 6-month follow-up TEE revealed a mobile thrombus (2.4 cm × 0.6 cm) at the 
atrial side of the WD. Therapy with intravenous heparin was started. However, a control TEE examination 
after one week revealed progression of the thrombus size (4.2 cm × 0.7 cm) and its protrusion across 
the mitral valve orifice into the left ventricle. Although the patient remained asymptomatic, cardiosurgical 
excision of the thrombus was performed due to high risk of thrombus embolization.
Conclusions. Late device-associated thrombus formation after implantation of the WD remains a rare but 
severe complication. Formal recommendations regarding prevention and management of device-related 
thrombosis are still lacking. In this complex clinical setting, we suggest: 1) careful long-term echocardio-
graphic monitoring after percutaneous LAA closure, especially in patients with permanent AF, high 
thromboembolic risk, large LA and dense spontaneous echo contrast in echocardiography, and 2) an 
individualized treatment approach. 
Key words: atrial fibrillation, thromboembolic risk, left atrial appendage closure, WatchmanTM device
Med Res J 2016; 1 (1): 48–52 
Corresponding author: 
Iwona Świątkiewicz MD, PhD 
Department of Cardiology, 
University Hospital No. 1,  
9 Sklodowskiej-Curie St.  
85–094 Bydgoszcz, Poland 
Phone +48 52 585 4023 
Fax +48 52 585-4024 
E-mail: iwona.swiatkiewicz@gmail.com
Introduction
Left atrial appendage (LAA) occlusion using percu-
taneous interventional techniques has been demon-
strated to be equivalent to oral anticoagulation (OA) 
in reducing thromboembolic events in patients with 
non-valvular atrial fibrillation (AF) [1–4]. The actually 
accepted indications for catheter-based LAA occlusion 
have been recently published in the EHRA/EAPCI expert 
consensus statement [5]. According to this document, 
catheter-based LAA occlusion may be considered [5]: 
 — as replacement for OA when OA is not possible (e.g. 
patients with a contraindication to OA, patients with 
increased bleeding risk under OA, patients who 
refuse OA);
 — as a complement to OA; 
 — as adjunct to ablation of AF, or as an alternative to 
OA even if OA is possible.
The Watchman™ device (WD) (Boston Scientific 
Corp., Marlborough, MA, USA), a first-of-its-kind, proven 
alternative to long-term OA, has shown its effectiveness 
and relative safety in AF patients who do not wish or 
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Figure 1. Left atrial appendage assessment before 
implantation of the WatchmanTM device. Transesophageal 
echocardiography: mid-esophageal views (1A — 47 
degrees; 1B — 90 degrees; 1C — 136 degrees)
cannot receive OA [1–3, 6]. Finally, the use of the WD 
was approved by the Food and Drug Administration on 
13 March 2015. However, implantation of the WD may 
be potentially associated with complications related to 
the transseptal puncture or placement of the device, 
such as pericardial effusion, device embolization, 
post-implantation sepsis and the presence of device-re-
lated thrombus [1–3, 7, 8].
Case report
A 65-year-old woman, with permanent non-valvu - 
lar AF, previous ischemic stroke on warfarin therapy, medi-
cated hypertension, diabetes mellitus, chronic heart fail-
ure with preserved left ventricular (LV) ejection fraction 
and labile values of the international normalized ratio 
(INR), was admitted to our department for the assess-
ment of indications and feasibility of the percutaneous 
LAA closure. Both thromboembolic and bleeding risk of 
the patient were high as indicated by the CHA2DS2-Vasc 
score (5 points) and the HAS-BLED score (4 points), 
respectively. In transthoracic echocardiography we 
observed left atrial (LA) enlargement, LV hypertrophy, 
lack of wall motion abnormalities and preserved LV 
systolic function. Transesophageal echocardiography 
(TEE) was subsequently performed to assess the 
width of LAA orifice, the depth of LAA and the presence 
of additional lobes as well as to exclude thrombi inside 
the LA (Fig. 1A–1C). We observed weak spontaneous 
echo contrast without any thrombi in the LA. The pa-
tient was qualified for the percutaneous LAA closure 
based on the high thromboembolic and bleeding 
risk and optimal LAA morphology for percutaneous 
occlusion. Successful percutaneous closure of LAA 
using a 30 mm-sized WD was performed by venous 
access and transseptal puncture, with no complica-
tions during the implantation. The correct positioning 
of the WD at the LAA ostium was demonstrated by 
both echocardiography and angiography. There was 
a small amount of pericardial effusion and absence of 
residual flow around the device using colour Doppler 
at the end of the procedure in TEE. The patient was 
on a daily dose of aspirin 100 mg and 100 U/kg in-
travenous heparin was added at the beginning of the 
procedure, followed by low-molecular-weight heparin 
(enoxaparin 2 × 80 mg s.c.) after the implantation. 
The OA using warfarin was started immediately after 
the procedure and was planned to be continued for 
45 days, maintaining the international normalized 
ratio (INR) values within the therapeutic range (i.e. 
between 2.0 and 3.0). However, the patient was dis-
charged on low-molecular-weight heparin (enoxaparin 
2 × 80 mg s.c.), because the target INR values were 
difficult to be kept (it was about 4.0). A scheduled TEE 
examination, performed 45 days after the procedure, 
showed normal position of the WD in the LAA, without 
residual peri-device flow, but with the presence of 
dense spontaneous echo contrast and small immobile 
echo on the atrial surface of the WD, suspected to 
be a small thrombus (Fig. 2A–2B). According to the 
results of TEE, warfarin instead of dual antiplatelet 
therapy (DAPT) was started, with the recommendation 








Figure 2. WatchmanTM device at 45 days after implantation 
into the left atrial appendage. Transesophageal echo-
cardiography: mid-esophageal views (2A — 90 degrees; 
2B — 134 degrees)
(2.0–3.0). The 6-month follow-up TEE revealed sponta-
neous echo contrast in the LA and a mobile thrombus 
(2.4 cm × 0.6 cm) located at the atrial side of the WD 
(Fig. 3A–3B) despite the appropriate OA therapy. 
Because of high risk of embolization, therapy with 
intravenous heparin was initiated immediately (aimed 
to maintain the activated partial thromboplastin time 
values > 2.5 times the patient’s baseline control). 
A control TEE examination, performed one week after 
heparin was started, showed decreased dimensions 
of the thrombus (1.7 cm × 0.5 cm), so heparin was re-
placed by low-molecular-weight heparin (enoxaparin 
2 × 80 mg s.c.). Another TEE examination, repeated 
after yet another week, revealed no resolution of the 
thrombus, which was still mobile, floating, with greater 
dimensions (4.2 cm × 0.7 cm), apparently originating 
from the screw’s lodging and protruding across the 
mitral valve orifice into the LV (Fig. 4A–4B). Despite 
the fact that the patient remained completely asymp-
tomatic, without any neurological event, cardiosurgical 
excision of the thrombus was performed due to high 
risk of thrombus embolization.
A
B
Figure 3. Thrombus formation (2.4 cm × 0.6 cm) on 
the atrial side of the WatchmanTM device 6 months after 
implantation. Transesophageal echocardiography: mid-
esophageal views (3A — 100 degrees; 3B — 90 degrees)
Discussion and literature review
LAA closure using the WD was reported to be ef-
fective for patients with AF to prevent stroke, systemic 
embolism and cardiovascular death, compared with 
warfarin therapy [1–3, 6]. However, this procedure is 
associated with the risk of the formation of thrombus 
attached to the WD [2, 5, 7, 8]. Acute thrombosis may 
occur as a result of incorrect device selection or im-
plantation (e.g. inadequate size, incorrect placement 
or instability of the device) [5, 7]. Chronic thrombosis 
is usually observed in the follow-up TEE examination 
between 45 days and 3 years after the WD implanta- 
tion [2, 5, 7–13]. It may be potentially triggered by incom-
plete closure of the LAA or increased thromboembolic 
risk in patients, predominantly resulting from the older 
age and the presence of multiple comorbidities [2, 5, 7, 8]. 
Antiplatelet and antithrombotic treatment introduced in 
patients undergoing catheter-based LAA occlusion is 
aimed to prevent device-related thrombus formation. In 
line with the protocol of the PROTECT AF-trial, the usu-
ally used in clinical practice peri- and post-procedural 
Iwona Świątkiewicz et al., Device-associated thrombus after percutaneous LAA closure
51www.journals.viamedica.pl/medical_research_journal
in patients with device-associated thrombus than in 
those without it [9]. 
Consistently with a case report by Elabbassi et al. 
describing a 75-year-old woman with device-related 
thrombus overlying a LA occlusion device implanted in 
the presence of persistent spontaneous contrast despite 
prolonged OA, we observed spontaneous contrast in 
the LA in pre-procedural and follow-up TEE examina-
tions in our patient [13]. In line with the findings of the 
above studies, it is recommended to perform TEE at 
45 days to 6 months after the implantation, since most 
thrombi were documented so far at 45-day TEE [5]. 
In the majority of studies, warfarin therapy was 
restarted or continued for another 4-8 weeks after de-
tection of device-related thrombus [5, 9, 10]. In some 
cases, low-molecular-heparin treatment may be also 
considered for another 4–8 weeks [5]. A control TEE 
examination is suggested to guide the decision regard-
ing further management. This approach appears to be 
successful in the majority of patients, especially in those 
with small thrombus. As reported by Kubo et al. and 
Saw et al., the thrombus disappeared in all patients at 
follow-up TEE examination, mostly within 6 months after 
the identification of device-associated thrombus [9, 10]. 
Therefore, anticoagulant therapy is recommended in all 
patients with device-associated thrombus regardless of 
the symptoms until thrombus resolution is confirmed by 
follow-up TEE [5]. As reported by Elabbassi et al. and 
observed in our patient, this kind of treatment regimen 
is not always successful, especially in patients with 
permanent AF, large LA and dense spontaneous echo 
contrast in TEE [13]. 
There is only little evidence on the association be-
tween the presence of device-attached thrombus and an 
increased incidence of thromboembolic events [2, 9, 10]. 
Acute stroke caused by air or thrombus embolization 
after implantation of the WD occurred in 1.1% of 478 pro-
cedures in the PROTECT AF trial during a mean fol-
low-up of just more than a year [2]. In the study by Kubo 
et al. there were no death, stroke and systemic embo-
lism events during a follow-up of 1456 ± 546 days [9]. 
In the Canadian multi-center registry, there was only 
1 case of transient ischemic attack and no stroke or death 
during a mean follow-up of 173.8 ± 117.3 days [10]. 
Unexpectedly, the patient discussed in this case report 
remained completely asymptomatic despite the pres-
ence of large, mobile thrombus in the LA.
There is no strict recommendation in the EHRA/ 
/EAPCI expert consensus statement on the indications 
for cardiac surgery in patients with device-related 
thrombosis [5]. In our opinion, cardiac surgery should 
be considered in patients with device-associated 
late thrombosis, especially if the thrombus is mobile, 
greater than 2.0 cm, with high risk of embolization, or 
in patients with a history of thromboembolic event. 
Figure 4. A huge (4.2 cm × 0.7 cm), mobile thrombus on 
the atrial side of the WatchmanTM device protruding across 
the mitral valve into the left ventricle (further examination 
at 6 months after implantation). Transesophageal 




antiplatelet and antithrombotic regimen comprises: 
aspirin 100 mg q.s. started before the intervention, an 
intravenous infusion of heparin during the procedure, 
followed by short-term OA with warfarin (for 45 days) 
and long-term DAPT (for 6 months) [1]. 
Device-associated thrombus, mostly non-mobile, 
was observed in 4.2% of 478 patients successfully treat-
ed with WD implantation in the PROTECT AF trial [2] 
and in 1.1% of 90 patients who underwent WD implanta-
tion on DAPT in the Canadian multi-center registry [10]. 
Additionally, Kubo et al. identified LA thrombus 
(usually non-mobile, smaller than 2.0 cm) attached 
to the WD in 3.4% of 119 implanted patients [9]. 
In this study, follow-up TEE examinations were per-
formed 45 days, 6 months or 12 months after the pro-
cedure and device-related thrombosis usually occurred 
after OA discontinuation. Similarly to our patient, the 
prevalence of permanent AF in the study by Kubo et 
al. was more common and the mean CHADS2 score 
tended to be higher (3.8 ± 0.6 vs. 2.5 ± 0.1; p = 0.06) 
Medical ReseaRch JouRnal 2016, vol. 1, no. 1
52 www.journals.viamedica.pl/medical_research_journal
As in the described case, such decision must be made 
after taking into account individual risk factors present 
in the particular patient.
Despite the already obtained evidence on the effec-
tiveness of percutaneous LAA closure, further studies 
are needed to evaluate the risk of late WD-related 
thrombosis and to investigate whether the common 
regimen with short-term OA, followed by long-term 
DAPT started already before the complete endotheliza-
tion of the device is sufficient to prevent device-asso-
ciated late thrombosis, especially in patients with high 
thromboembolic risk. Our case report exemplifies that 
device-associated late thrombosis may occur even 
during optimal long-term OA. Based on the observations 
by Kaul et al., we believe that non-vitamin K antagonist 
oral anticoagulants (NOACs) may constitute a valuable 
alternative in subjects undergoing WD implantation [14].
Conclusions
Device-associated thrombus formation in long-term 
follow-up after the implantation of the WD remains a rare 
but severe complication. Formal recommendations 
regarding prevention and management of device-re-
lated thrombosis are still lacking. Careful long-term 
echocardiographic monitoring seems reasonable after 
percutaneous LAA closure, especially in high throm-
boembolic risk patients (e.g. those with permanent 
AF, large LA and dense spontaneous echo contrast in 
echocardiography). Prolongation of OA with warfarin 
or treatment with NOACs after the implantation of WD 
should be considered individually in these high-risk 
patients. Finally, due to the paucity of evidence-based 
data, we suggest an individualized treatment approach 
in patients with device-associated thrombus after per-
cutaneous LAA closure.
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